Kura Oncology (KURA) Total Non-Current Liabilities (2014 - 2026)

Kura Oncology (KURA) has 13 years of Total Non-Current Liabilities data on file, last reported at $541.2 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 43.48% year-over-year to $541.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $541.2 million (up 43.48% YoY) and the FY2025 annual result came in at $561.1 million, up 62.76% from the prior year.
• Total Non-Current Liabilities eased to $541.2 million in Q1 2026 per KURA's latest filing, from $561.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $561.1 million in Q4 2025 and bottomed at $21.5 million in Q2 2022.
• The 5-year median for Total Non-Current Liabilities is $47.9 million (2024), against an average of $177.5 million.
• The widest annual swing landed in 2022, when Total Non-Current Liabilities slumped 35.45%; it then soared 687.96% in 2025.
• Tracing KURA's Total Non-Current Liabilities over 5 years: stood at $35.8 million in 2022, then surged by 42.49% to $51.0 million in 2023, then soared by 576.5% to $344.7 million in 2024, then soared by 62.76% to $561.1 million in 2025, then dropped by 3.53% to $541.2 million in 2026.
• Per Business Quant, the three latest KURA Total Non-Current Liabilities figures stand at $541.2 million (Q1 2026), $561.1 million (Q4 2025), and $403.9 million (Q3 2025).

Peer Comparison